Release Date ![[down]](http://us.i1.yimg.com/us.yimg.com/i/fi/down.gif) |
Contributor |
Author |
Title |
Pages |
Price |
StarMine Author Rating | More Info |
| EPS Accuracy * |
Portfolio Return ** |
| 11-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | MELA: 3Q Update: Net Loss Widens Slightly; Likely No MelaFind for Xmas | 6 | $25 | | | View Abstract |
| 11-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | EAR: EPS Inline Despite Light Revenue; AARP Coming into View | 8 | $25 | | | View Abstract |
| 9-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | 3Q Basically Inline; New Products Drive Growth & Profitability Next Year; Buy | 8 | $25 | | | View Abstract |
| 9-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | 3Q Results Light; Future Uncertain Despite Patient Vol; Rating, PT Under Review | 4 | $10 | | | View Abstract |
| 9-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Upgrading to Buy: Coming Out of the Trough with Expanding EPS; Target $15 | 6 | $25 | | | View Abstract |
| 9-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | OSTE: Another Disappointing Quarter; New Product Success is a Must | 8 | $25 | | | View Abstract |
| 6-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Alphatec (ATEC) 3Q09 Earnings Preview | 3 | $10 | | | View Abstract |
| 6-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Product Revs Essentially Inline; Data & Japan Fuel 2010 Growth, Profit; Buy | 8 | $25 | | | View Abstract |
| 5-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | 4Q Picking Back Up; CORTOSS Rollout Progressing, Will Take a Little Time; Buy | 8 | $25 | | | View Abstract |
| 5-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | MELA: Approval Equally Probable but Timeline Appears Extended | 3 | $10 | | | View Abstract |
| 5-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | 3Q Inline with Preannouncement; Sales Light on Distractions; Call 830AM | 3 | $10 | | | View Abstract |
| 4-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Orthovita Inc. (VITA) 3Q09 Earnings Preview | 3 | $10 | | | View Abstract |
| 4-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Raising Target on DOJ Settlement; 3Q Revs Inline w/ Good Cost Control | 8 | $25 | | | View Abstract |
| 4-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Volcano Corporation (VOLC) 3Q09 Earnings Preview | 4 | $10 | | | View Abstract |
| 4-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Lowering Target: 3Q Messy on Payor Issues; LT Fundamentals Appear Intact | 8 | $25 | | | View Abstract |
| 4-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Bounce Back in 3Q; Rainbow Picking Up; Reiterate Buy | 8 | $25 | | | View Abstract |
| 3-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | AtriCure (ATRC) 3Q09 Earnings Preview | 3 | $10 | | | View Abstract |
| 2-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | 3Q & FY09 Outlook Beat on All Fronts; 2010 Guidance Possibly Conservative; Buy | 8 | $25 | | | View Abstract |
| 2-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Masimo Corporation (MASI) 3Q09 Earnings Preview | 4 | $10 | | | View Abstract |
| 2-Nov-09 | Roth Capital Partners, Inc. | Matt Dolan | Clarient, Inc. (CLRT) 3Q09 Earnings Preview | 4 | $10 | | | View Abstract |